Xenon Pharmaceutical Reports Positive Results of XEN1101 P-1b TMS (transcranial magnetic stimulation) study

 Xenon Pharmaceutical Reports Positive Results of XEN1101 P-1b TMS (transcranial magnetic stimulation) study

Xenon Pharmaceutical Reports Positive Results of XEN1101 P-1b TMS (transcranial magnetic stimulation) study

Shots:
  •   This study enrolled 20 healthy males while measuring endpoint at 2, 4 & 6hrs. administering 20mg of XEN1101 or PBO showing its safety and tolerability
  •   P-Ib TMS results: TMS-EMG measure- single 20mg of XEN1101 resulted in (plasma levels of 15.7 ,30.2 and 44.4 ng/mL at 2, 4 & 6hrs.); RMT (1.5±0.4%, 3.0±0.7%, 4.3±0.8%)
  •   With completion of XEN1101 P-I it is expected to initiate P-II trial, a treatment for adult focal seizures in Q4’18
Click here to read full press release/ article | Ref: Xenon | Image:  Society of generic physiologists

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post